• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by RadNet Inc.

    7/22/25 5:28:58 PM ET
    $RDNT
    Medical Specialities
    Health Care
    Get the next $RDNT alert in real time by email
    S-8 1 radnet_s8.htm S-8

    As filed with the Securities and Exchange Commission on July 22, 2025

     

    Registration No. 333-         

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

     

    FORM S-8

    REGISTRATION STATEMENT

    UNDER THE SECURITIES ACT OF 1933

     

     

     

    RADNET, INC.

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware       13-3326724

    (State or other jurisdiction of

    incorporation or organization)

         

    (I.R.S. Employer

    Identification No.)

     

     

     

    1510 Cotner Avenue

    Los Angeles, California

    (Address of Principal Executive Offices)

    90025

     

     

    (Zip Code)

    (Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

     

     

     

    iCAD, Inc. 2016 Stock Incentive Plan, as amended

    iCAD, Inc. 2012 Stock Incentive Plan, as Amended by Amendment No. 1

    (Full title of the plans)

     

     

     

    Howard G. Berger, M.D.

    President and Chief Executive Officer

    RadNet, Inc.

    1510 Cotner Avenue

    Los Angeles, California 90025

    (Name and address of agent for service)

     

    (310) 445-2800

    (Telephone number, including area code, of agent for service)

     

     

     

    With copies to:

     

    Andrew Moore

    Jonathan S. Schulman

    Christopher Wassman

    Perkins Coie LLP

    1301 Second Avenue, Suite 4200

    Seattle, Washington 98101

    (206) 359-8000

     

     

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and "emerging growth company" in Rule 12b-2 of the Exchange Act:

     

    Large accelerated filer   x   Accelerated filer   ¨
           
    Non-accelerated filer   ¨   Smaller reporting company   ¨
        Emerging growth company   ¨
         
    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.   ¨
                   

     

       

     

     

    EXPLANATORY NOTE

     

    On July 17, 2025, pursuant to the Agreement and Plan of Merger (the “Merger Agreement”), dated as of April 15, 2025, by and among RadNet, Inc., a Delaware corporation (the “Registrant” or “RadNet”), Trio Merger Sub, Inc., a wholly-owned subsidiary of RadNet and a Delaware corporation (“Merger Sub”), and iCAD, Inc., a Delaware corporation (“iCAD”), Merger Sub merged with and into iCAD, with iCAD surviving as a wholly-owned subsidiary of RadNet (the “Merger”).

     

    The Registrant hereby files this Registration Statement on Form S-8 relating to up to 106,591 shares of the Registrant’s common stock, par value $0.0001 per share, issuable with respect to certain options to purchase shares of iCAD’s common stock, par value $0.01 per share, granted under the iCAD, Inc. 2016 Stock Incentive Plan, as amended, and the iCAD, Inc. 2012 Stock Incentive Plan, as amended by Amendment No. 1 (collectively, the “Plans”), which options were assumed by the Registrant pursuant to the Merger Agreement in connection with the consummation of the Merger. 

     

     

     

     2 

     

     

    PART I

    INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS

     

    Item 1.Plan Information

     

    The document(s) containing the information specified in Part I of Form S-8 will be sent or given to participants in the Plans as specified by Rule 428(b)(1) under the Securities Act of 1933, as amended (the “Securities Act”). Such documents are not being filed with the Securities and Exchange Commission (the “Commission”) but constitute, along with the documents incorporated by reference into this Registration Statement pursuant to Item 3 of Part II of this Form S-8, a prospectus that meets the requirements of Section 10(a) of the Securities Act.

     

    Item 2.Registrant Information and Employee Plan Annual Information

     

    The written statement required by Item 2 of Part I is included in documents delivered to participants in the Plans covered by this Registration Statement pursuant to Rule 428(b) of the Securities Act.

     

    PART II

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    Item 3. Incorporation of Documents by Reference.

     

    This Registration Statement incorporates herein by reference the following documents, which have been filed with the Commission by the Registrant:

      

      •   Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the SEC on March 3, 2025, as amended by Amendment No. 1 on Form 10-K/A, filed with the SEC on April 28, 2025;
      •   The Part III information contained in the Registrant’s definitive proxy statement on Schedule 14A for RadNet’s 2025 annual meeting of stockholders, filed with the SEC on April 28, 2025, that was incorporated into the Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the SEC on March 3, 2025.
      •   Registrant’s Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2025, filed with the SEC on May 12, 2025;
      •   Registrant’s Current Report on Form 8-K filed with the SEC on June 12, 2025;
      •   The description of the Registrant’s securities contained in Exhibit 4.1 to the Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the SEC on March 3, 2025, and in any report filed for the purpose of amending such description.

     

    All documents subsequently filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), prior to the filing of a post-effective amendment that indicates that all securities offered have been sold or that deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference in this Registration Statement and to be part hereof from the respective date of filing of such documents (other than information furnished under Item 2.02 and Item 7.01 of Form 8-K).

     

    Any statement contained in this Registration Statement, in an amendment hereto or in a document incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any subsequently filed amendment or supplement to this Registration Statement or in any document that is incorporated by reference herein modifies or supersedes such statement. Any statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

     

    Item 4. Description of Securities.

     

    Not Applicable.

     

    Item 5. Interests of Named Experts and Counsel.

     

    Not Applicable.

     

     

     3 

     

     

    Item 6. Indemnification of Directors and Officers.

     

    Delaware Law, Certificate of Incorporation, and Bylaws

     

    The following provisions of Delaware law and RadNet’s Certificate of Incorporation and Bylaws govern the indemnification of RadNet’s directors and officers.

     

    Section 145 of the Delaware General Corporation Law (“DGCL”) permits a corporation to indemnify any director, officer, employee or agent of the corporation, or other person who is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, any such person we refer to as an indemnitee, against expenses (including attorney’s fees), judgments, fines and amounts paid in settlement actually and reasonably incurred in connection with any action, suit or proceeding brought by reason of the fact that the indemnitee is or was serving the corporation or another entity at the direction of the corporation, provided that the indemnitee acted in good faith and in a manner that he or she reasonably believed to be in, or not opposed to, the best interests of the corporation, and, with respect to any criminal action or proceeding, if he or she had no reason to believe his or her conduct was unlawful. In a derivative action (i.e., one brought by or on behalf of the corporation), indemnification may be provided only for expenses actually and reasonably incurred by the indemnitee in connection with the defense or settlement of such an action or suit if the indemnitee acted in good faith and in a manner that he or she reasonably believed to be in, or not opposed to, the best interests of the corporation, except that no indemnification shall be provided if the indemnitee is adjudged to be liable to the corporation, unless and only to the extent that the court in which the action or suit was brought determines that the indemnitee is fairly and reasonably entitled to indemnity for his or her expenses despite the adjudication of liability.

     

    Section 145(g) of the DGCL also provides that a corporation may maintain insurance against liabilities even if the corporation would lack the power under the DGCL to indemnify against those liabilities.

     

    Article Ninth of RadNet’s Certificate of Incorporation, as amended (“Certificate of Incorporation”) provides that a director is not liable to RadNet or its stockholders for monetary damages for breach of fiduciary duty as a director to the fullest extent permitted by the DGCL. It further obligates RadNet, with respect to its officers and directors, and permits RadNet, with respect to its employees and agents, to indemnify, in the manner and to the fullest extent permitted by the DGCL, any person (or the estate of any person) who is or was a party to, or is threatened to be made a party to, any threatened, pending or completed action, suit or proceeding, whether or not by or in the right of RadNet, and whether civil, criminal, administrative, investigative or otherwise, by reason of the fact that the person is or was a director or officer, or employee or agent, as the case may be, of RadNet, or is or was serving at the request of RadNet as a director or officer, or employee or agent, as the case may be, of another corporation or entity. RadNet may advance the expenses incurred by any such director, officer, employee or agent in defending any such action, suit or proceeding prior to its final disposition upon receipt of an undertaking by the recipient to repay the amounts advanced if it is ultimately determined that he or she is not entitled to be indemnified as authorized by the DGCL and RadNet’s Certificate of Incorporation. To the fullest extent permitted by the DGCL, the indemnification provided in the certificate of incorporation includes expenses (including attorneys’ fees), judgments, fines and amounts paid in settlement and, in the manner provided by the DGCL, RadNet may pay any of these expenses in advance of the final disposition of such action, suit or proceeding.

     

    Except as described in this paragraph, Article VII of RadNet’s Amended and Restated Bylaws (“Bylaws”) contains provisions substantially similar to Article Ninth of RadNet’s Certificate of Incorporation. In addition, RadNet’s Bylaws obligate RadNet to indemnify each of its officers, directors, employees and agents in any action, suit or proceeding referred to above to the extent that person has been successful on the merits in defense thereof, or in defense of any claim, issue or matter therein, against expenses (including attorneys’ fees) actually and reasonably incurred by that person in connection therewith. RadNet’s Bylaws obligate RadNet to advance expenses to its officers and directors, and require an undertaking to repay expenses under the specified conditions if required by applicable law.

     

    General

     

    RadNet also maintains insurance for its officers and directors against certain liabilities, including liabilities under the Securities Act. The effect of this insurance is to indemnify any of RadNet’s officers or directors against expenses, including attorneys’ fees, judgments, fines and amounts paid in settlement, incurred by an officer or director upon a determination that such person acted in good faith. RadNet pays the premiums for this insurance.

     

     

     4 

     

     

    RadNet has also entered into separate indemnification agreements with its officers and directors, which indemnify the officer or director against all liabilities relating to his or her position as an officer or director of RadNet, or as an employee, agent, officer or director of any other entity if the officer or director is serving in that capacity at RadNet’s request, to the fullest extent permitted under applicable law.

     

    Insofar as indemnification for liabilities arising under the Securities Act may be permitted to RadNet’s directors, officers or controlling persons pursuant to the foregoing provisions, RadNet has been informed that, in the opinion of the SEC, such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In addition, indemnification for violations of state securities laws may be limited by applicable laws.

     

    Item 7. Exemption from Registration Claimed. 

     

    Not Applicable.

     

    Item 8. Exhibits.

     

    EXHIBIT INDEX

     

      

    Exhibit No. Description

     

    4.1*   Certificate of Incorporation of RadNet, Inc. (incorporated by reference to Exhibit 3.1 to RadNet, Inc.’s Current Report on Form 8-K, filed on September 4, 2008).
         
    4.2*   Certificate of Amendment to Certificate of Incorporation of RadNet, Inc., dated September 2, 2008 (incorporated by reference to Exhibit 3.2 to RadNet, Inc.’s Current Report on Form 8-K, filed on September 4, 2008).
         
    4.3*   Amended and Restated Bylaws of RadNet, Inc. (incorporated by reference to Exhibit 3.1 to RadNet, Inc.’s Current Report on Form 8-K, filed on February 6, 2020).
         
    5.1   Opinion of Perkins Coie LLP.
         
    10.1*   iCAD, Inc. 2016 Stock Incentive Plan, as amended July 2021 (incorporated by reference to Appendix B of the Definitive Proxy on Schedule 14A of iCAD, filed on June 7, 2021) (File No. 001-09341).
         
    10.2*   iCAD, Inc. 2012 Stock Incentive Plan (incorporated by reference to Appendix B of the Definitive Proxy on Schedule 14A of iCAD, filed on April 9, 2012) (File No. 001-09341).
         
    10.3*   Amendment No. 1 to the iCAD, Inc. 2012 Stock Incentive Plan (incorporated by reference to Appendix A of the Definitive Proxy on Schedule 14A of iCAD, filed on April 2, 2014) (File No. 001-09341).
         
    23.1   Consent of Independent Registered Public Accounting Firm.
         
    23.2   Consent of Perkins Coie LLP (contained in Exhibit 5.1).
         
    24.1   Power of Attorney (see signature page of this Registration Statement).
         
    107   Filing Fee Table.

     

     
    * Incorporated by reference to the indicated filing.

     

     

     5 

     

     

    Item 9. Undertakings.

     

    (a) The undersigned Registrant hereby undertakes:

     

    (1) To file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:

     

    (i) To include any prospectus required by Section 10(a)(3) of the Securities Act;

     

    (ii) To reflect in the prospectus any facts or events arising after the effective date of this Registration Statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in this Registration Statement; and

     

    (iii) To include any material information with respect to the plan of distribution not previously disclosed in this Registration Statement or any material change to such information in this Registration Statement;

     

    Provided, however, that the undertakings set forth in paragraphs (a)(1)(i) and (a)(1)(ii) above do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the Registrant pursuant to Section 13 or Section 15(d) of the Exchange Act that are incorporated by reference in this Registration Statement.

     

    (2) That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

     

    (3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

     

    (b) The undersigned Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the Registrant’s annual report pursuant to Section 13(a) or Section 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in this Registration Statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

     

    (c) Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

     

     

     6 

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Lost Angeles, State of California, on July 22, 2025.

     

     

      RADNET, INC.
         
      By: /s/ Howard G. Berger, M.D.
        Howard G. Berger, M.D.
        Chief Executive Officer and Director

     

    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby severally constitutes and appoints Howard G. Berger, M.D. and Mark D. Stolper, and each of them, his or her true and lawful attorney-in-fact and agent, with full power of substitution and re-substitution for him or her and in his or her name, place and stead, in any and all capacities to sign any and all amendments to this registration statement, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite or necessary fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that each said attorneys-in-fact and agents or any of them or their or his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

     

     

    Signature 

     

    Title 

     

    Date 

         

    /s/ Howard G. Berger, M.D. 

    Howard G. Berger, M.D. 

     

    Chief Executive Officer and Director

    (Principal Executive Officer)

      July 22, 2025
             

    /s/ Gregory E. Spurlock

    Gregory E. Spurlock 

      Director   July 22, 2025
             

    /s/ Alma Gregory Sorensen

     Alma Gregory Sorensen 

      Director   July 22, 2025
         

    /s/ David L. Swartz 

    David L. Swartz

     

      Director   July 22, 2025
    /s/ Lawrence L. Levitt    

    Lawrence L. Levitt

     

      Director   July 22, 2025
    /s/ Laura P. Jacobs    

    Laura P. Jacobs

     

      Director   July 22, 2025

     

    /s/ Mark D. Stolper        
     

    Mark D. Stolper

     

     

    Chief Financial Officer

    (Principal Financial Officer and Principal Accounting Officer)

      July 22, 2025

     

     

     7 

     

    Get the next $RDNT alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $RDNT

    DatePrice TargetRatingAnalyst
    6/13/2025$69.00Buy
    B. Riley Securities
    3/5/2025$85.00 → $65.00Outperform → Strong Buy
    Raymond James
    9/6/2024$57.00 → $79.00Equal Weight → Overweight
    Barclays
    3/6/2024$48.00Equal Weight
    Barclays
    8/31/2023$40.00Buy
    Truist
    3/31/2023$30.00Market Outperform
    CJS Securities
    3/3/2023$30.00Mkt Perform → Outperform
    Raymond James
    8/12/2021Outperform → Market Perform
    Raymond James
    More analyst ratings

    $RDNT
    SEC Filings

    See more
    • SEC Form S-8 filed by RadNet Inc.

      S-8 - RadNet, Inc. (0000790526) (Filer)

      7/22/25 5:28:58 PM ET
      $RDNT
      Medical Specialities
      Health Care
    • SEC Form POS AM filed by RadNet Inc.

      POS AM - RadNet, Inc. (0000790526) (Filer)

      7/22/25 5:28:01 PM ET
      $RDNT
      Medical Specialities
      Health Care
    • RadNet Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - RadNet, Inc. (0000790526) (Filer)

      7/17/25 4:30:49 PM ET
      $RDNT
      Medical Specialities
      Health Care

    $RDNT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • B. Riley Securities initiated coverage on RadNet with a new price target

      B. Riley Securities initiated coverage of RadNet with a rating of Buy and set a new price target of $69.00

      6/13/25 7:50:00 AM ET
      $RDNT
      Medical Specialities
      Health Care
    • RadNet upgraded by Raymond James with a new price target

      Raymond James upgraded RadNet from Outperform to Strong Buy and set a new price target of $65.00 from $85.00 previously

      3/5/25 7:50:00 AM ET
      $RDNT
      Medical Specialities
      Health Care
    • RadNet upgraded by Barclays with a new price target

      Barclays upgraded RadNet from Equal Weight to Overweight and set a new price target of $79.00 from $57.00 previously

      9/6/24 7:50:42 AM ET
      $RDNT
      Medical Specialities
      Health Care

    $RDNT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • EVP, Chief Science Officer Sorensen Alma Gregory gifted 5,600 shares, decreasing direct ownership by 0.48% to 1,165,345 units (SEC Form 4)

      4 - RadNet, Inc. (0000790526) (Issuer)

      6/18/25 4:15:24 PM ET
      $RDNT
      Medical Specialities
      Health Care
    • Director Swartz David L was granted 2,699 shares, increasing direct ownership by 2% to 176,766 units (SEC Form 4)

      4 - RadNet, Inc. (0000790526) (Issuer)

      6/11/25 6:58:58 PM ET
      $RDNT
      Medical Specialities
      Health Care
    • Director Spurlock Gregory E. was granted 2,699 shares, increasing direct ownership by 104% to 5,290 units (SEC Form 4)

      4 - RadNet, Inc. (0000790526) (Issuer)

      6/11/25 6:57:48 PM ET
      $RDNT
      Medical Specialities
      Health Care

    $RDNT
    Leadership Updates

    Live Leadership Updates

    See more
    • RadNet, Inc. Announces the Appointment of Kees Wesdorp as President and Chief Executive Officer of RadNet's Digital Health Division

      Former Chief Business Leader of Philips' multi-billion-dollar Precision Diagnosis division and member of Philips' Executive CommitteeEnd-to-end responsibility for Philip's CT, MR, dXR, Ultrasound and Diagnostic Informatics (radiology software) businessesProven track record of building and managing radiology software solutions, including significant experience with AI development and commercialization LOS ANGELES, Sept. 12, 2024 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ:RDNT), a national leader in providing high-quality, cost-effective diagnostic imaging services through a network of fully-owned and operated outpatient imaging centers and digital health solutions, announced today the appo

      9/12/24 6:00:00 AM ET
      $RDNT
      Medical Specialities
      Health Care

    $RDNT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by RadNet Inc.

      SC 13G/A - RadNet, Inc. (0000790526) (Subject)

      11/12/24 4:51:53 PM ET
      $RDNT
      Medical Specialities
      Health Care
    • Amendment: SEC Form SC 13G/A filed by RadNet Inc.

      SC 13G/A - RadNet, Inc. (0000790526) (Subject)

      11/4/24 1:22:38 PM ET
      $RDNT
      Medical Specialities
      Health Care
    • Amendment: SEC Form SC 13G/A filed by RadNet Inc.

      SC 13G/A - RadNet, Inc. (0000790526) (Subject)

      10/24/24 6:36:21 PM ET
      $RDNT
      Medical Specialities
      Health Care

    $RDNT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • RadNet, Inc. Announces Date of its Second Quarter 2025 Financial Results Conference Call

      LOS ANGELES, July 25, 2025 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ:RDNT), a national leader in providing high-quality, cost-effective diagnostic imaging services through a network of owned and operated outpatient imaging centers and digital health solutions, announced today that it will host a conference call to discuss its second quarter 2025 financial results on Monday, August 11, 2025 at 7:30 a.m. Pacific Time (10:30 a.m. Eastern Time). Investors are invited to listen to RadNet's conference call by dialing 844-826-3035. International callers can dial 412-317-5195. There will also be simultaneous and archived webcasts available at https://viavid.webcasts.com/starthere.jsp?ei=1729070&

      7/25/25 6:00:00 AM ET
      $RDNT
      Medical Specialities
      Health Care
    • RadNet's Wholly-Owned Subsidiary, DeepHealth, Completes Acquisition of iCAD

      Acquisition contributes iCAD's commercial, technology, and regulatory capabilitiesThe acquisition positions DeepHealth with an industry-leading suite of AI-powered breast cancer image interpretation and workflow solutionsThe combination is expected to provide acceleration of AI adoption and expanded worldwide access to advanced breast cancer screening and diagnosis technologies LOS ANGELES, July 17, 2025 (GLOBE NEWSWIRE) --  RadNet, Inc. (NASDAQ:RDNT) ("RadNet"), a national leader in providing high-quality, cost-effective diagnostic imaging services and digital health solutions, announced today that it has completed the acquisition of iCAD, Inc. (NASDAQ:ICAD) ("iCAD"), a global lead

      7/17/25 9:00:00 AM ET
      $ICAD
      $RDNT
      Medical/Dental Instruments
      Health Care
      Medical Specialities
    • Regal Medical Group, Lakeside Community Healthcare and ADOC Medical Group Add RadNet's AI-Powered Enhanced Breast Cancer Detection (EBCD) Program to its Membership Benefits in Southern California

      Program will increase access to cutting-edge AI-powered breast cancer detection and is designed to boost compliance with annual cancer-screening guidelinesRegal Medical Group, Lakeside Community Healthcare and ADOC Medical Group are affiliates of one of Southern California's largest health networks, which manages nearly 600,000 members from newborns to Medicare recipientsRegal Medical Group, Lakeside Community Healthcare and ADOC Medical Group contract with most major health insurance carriers, expanding access to quality care to communities across Southern California Program is indicative of EBCD reimbursement traction RadNet is getting with commercial payors LOS ANGELES, July 09, 2025 (

      7/9/25 6:00:00 AM ET
      $RDNT
      Medical Specialities
      Health Care

    $RDNT
    Financials

    Live finance-specific insights

    See more
    • RadNet, Inc. Announces Date of its Second Quarter 2025 Financial Results Conference Call

      LOS ANGELES, July 25, 2025 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ:RDNT), a national leader in providing high-quality, cost-effective diagnostic imaging services through a network of owned and operated outpatient imaging centers and digital health solutions, announced today that it will host a conference call to discuss its second quarter 2025 financial results on Monday, August 11, 2025 at 7:30 a.m. Pacific Time (10:30 a.m. Eastern Time). Investors are invited to listen to RadNet's conference call by dialing 844-826-3035. International callers can dial 412-317-5195. There will also be simultaneous and archived webcasts available at https://viavid.webcasts.com/starthere.jsp?ei=1729070&

      7/25/25 6:00:00 AM ET
      $RDNT
      Medical Specialities
      Health Care
    • RadNet's Wholly-Owned Subsidiary, DeepHealth, Completes Acquisition of iCAD

      Acquisition contributes iCAD's commercial, technology, and regulatory capabilitiesThe acquisition positions DeepHealth with an industry-leading suite of AI-powered breast cancer image interpretation and workflow solutionsThe combination is expected to provide acceleration of AI adoption and expanded worldwide access to advanced breast cancer screening and diagnosis technologies LOS ANGELES, July 17, 2025 (GLOBE NEWSWIRE) --  RadNet, Inc. (NASDAQ:RDNT) ("RadNet"), a national leader in providing high-quality, cost-effective diagnostic imaging services and digital health solutions, announced today that it has completed the acquisition of iCAD, Inc. (NASDAQ:ICAD) ("iCAD"), a global lead

      7/17/25 9:00:00 AM ET
      $ICAD
      $RDNT
      Medical/Dental Instruments
      Health Care
      Medical Specialities
    • RadNet, Inc. Acquires See-Mode Technologies for Innovation in AI-Powered Ultrasound Diagnostics

      See-Mode's commercially available AI-powered ultrasound detection, characterization, and reporting solutions for thyroid and breast will be integrated into RadNet's DeepHealth population health solutionsReal-world deployment of See-Mode's FDA-approved thyroid ultrasound solution at RadNet imaging centers demonstrates improved workflow efficiency and enhanced diagnostic accuracy The acquisition positions RadNet at the forefront of AI innovation in ultrasound LOS ANGELES, June 04, 2025 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ:RDNT) ("RadNet"), a national leader in providing high-quality, cost-effective diagnostic imaging services and digital health solutions through its wholly-owned subsidi

      6/4/25 4:01:00 PM ET
      $RDNT
      Medical Specialities
      Health Care